TSW
IONS icon

Thompson Siegel & Walmsley’s Ionis Pharmaceuticals IONS Stock Holding History

Thompson Siegel & Walmsley’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-28
Closed -$1K – 901
2016
Q4 		$1K Buy
+28
New +$1.11K ﹤0.01% 825

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Thompson Siegel & Walmsley's IONS Position: Q1 2017 in Review

Thompson Siegel & Walmsley sold out of Ionis Pharmaceuticals (IONS) in Q1 2017, closing a stake of 28 shares — an estimated $1K sold.

Thompson Siegel & Walmsley first reported a position in IONS in Q4 2016 and held it in 1 quarter. The position peaked at $1K in Q4 2016. 270 funds tracked by Wall St. Rank hold IONS as of Q1 2017.

  • Thompson Siegel & Walmsley reported no remaining Ionis Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 28 Ionis Pharmaceuticals shares in Q1 2017, an estimated $1K.
  • Thompson Siegel & Walmsley first reported a position in Ionis Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Thompson Siegel & Walmsley's Ionis Pharmaceuticals position peaked at $1K in Q4 2016.
  • 270 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2017.

Based on Thompson Siegel & Walmsley's 13F filing for Q1 2017, filed 15 May 2017.